A Clinically Validated pH-Sensitive Nanomedicine Platform for Encapsulating Therapeutic Bispecific T Cell Engagers for Tumor Specific Delivery and Activation

Brad Good

Brad Good is a Circle Platinum Squarespace expert and Authorized Trainer who has built on the platform since 2008, with more than 1,900 sites to his name. He makes Language Switch, a multilingual plugin for Squarespace 7.1, and writes the guides on this site.

http://www.bradgood.net
Previous
Previous

ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile

Next
Next

A polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates